Publications, Pharmaceutical

Developing a Dry Powder Formulation for Aptar Pharma Prohaler®

Aptar Pharma Prohaler® is a novel, high performance, multidose dry powder inhaler device with a patient-centric design developed to promote patient compliance.

This paper describes the optimization of a model formulation for Prohaler® via manipulation of the concentration of fine lactose and the inclusion of a force control agent, to reduce the strength of interparticle forces and promote dose deaggregation. The relationship between formulation composition and dissolution profile was also investigated. The inclusion of a force control agent was shown to be highly beneficial in promoting aerosolization, resulting in a higher fine particle mass and a finer mass median aerodynamic diameter. This effect was robust with respect to lactose fine concentration which in the absence of a force control agent was also observed to correlate positively with fine particle mass. Consideration of the use of force control agents is highly recommended when developing formulations for Prohaler®.

Download Publication
8 May 2021

Learn more about Prohaler®

Find Out More

This Might Also Be of Interest

12 Jul 2022

Digital Health and Digital Therapeutics: Where are we heading and...

Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
12 Jul 2022

How pMDIs are transforming Asthma and COPD treatments

Publications, Pharmaceutical, Sustainability, Device Innovations, Market Insights, Product Solutions

Read More
5 Jul 2022

Drug, Device, Digital: Reimagined Healthcare

Webinars, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions

Read More
30 Jun 2022

Supporting Patients and HCPs with New Digital Technology

Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 2 3 14
Back To Top